questioned whether adjuvant mediastinal radiotherapy (RT) is necessary for all patients at this stage after mediastinal lymph node dissection (not sampling), and suggested that perhaps only high-risk groups should be considered for adjuvant mediastinal RT for
Search Results
Abdul-Rahman Jazieh, Hanaa Bamefleh, Ahmet Demirkazik, Rabab Mohamed Gaafar, Fady B. Geara, Mansur Javaid, Jamal Khader, Kian Khodadad, Walid Omar, Ahmed Saadeddin, Hassan Al Sabe, Mohammad Behgam Shadmehr, Amgad El Sherif, Najam Uddin, Mohammad Jahanzeb, and David Ettinger
Angela Jain, Paula D. Ryan, and Michael V. Seiden
of ascitic fluid or peritoneal lavage, total abdominal hysterectomy, omentectomy, aortic and pelvic lymph node dissection, and complete debulking of any visible tumor (which may include bowel, liver, distal pancreatic resection, partial cystectomy
Presenter: Genevieve Boland
we should surveil them.” Lymph Node Dissection Dr. Boland reminded clinicians that many patients with early-stage disease can be cured with surgery alone. Management of this patient population begins with a wide local excision and in some cases
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder
-term survival. Lymph node dissection is not considered therapeutic but does provide prognostic information, because virtually all patients with nodal involvement subsequently relapse with distant metastases despite lymphadenectomy. The updated EORTC phase III
Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth K. O'Donnell, Elizabeth R. Plimack, Kim A. Margolin, Charles J. Ryan, Joel Sheinfeld, and Darren R. Feldman
retroperitoneal lymph node dissection (RPLND), although RPLND is reserved for specialty centers and is currently less often used. 6 All 3 strategies are well studied, and adjuvant BEP chemotherapy versus RPLND was subjected to a prospective randomized study by
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
recommendations for situations where axillary lymph node dissection (ALND) can be omitted in women with stages I, II, and IIIA (T3N1M0) breast cancer; for whole-breast radiation therapy (WBRT) using hypofractionation, updates regarding accelerated partial breast
Chunkit Fung, Sophie D. Fossa, Clair J. Beard, and Lois B. Travis
Cisplatin-based chemotherapy 22 and retroperitoneal lymph node dissection (RPLND) 23 – 25 are the cornerstones of nonseminoma management. Radiation treatment is generally reserved for patients with symptomatic metastases that are resistant to chemotherapy
Prajnan Das, Norio Fukami, and Jaffer A. Ajani
after gastrectomy for gastric cancer: data from a large US-population database . J Clin Oncol 2005 ; 23 : 7114 – 7124 . 21. Bonenkamp JJ Hermans J Sasako M . Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group
for Breast Cancer. “An incredible amount of progress has been made in surgical procedures and treatment based on tumor characteristics.” From a surgical standpoint, said Dr. Gradishar, axillary lymph node dissection was the standard of care in 1996
Eve Henry, Victor Villalobos, Lynn Million, Kristin C. Jensen, Robert West, Kristen Ganjoo, Alexandra Lebensohn, James M. Ford, and Melinda L. Telli
have a 2.7-cm moderately differentiated invasive ductal carcinoma that was estrogen receptor–positive/progesterone receptor–positive/HER2-positive (ER+/PR+/HER2+) on immunohistochemistry. Lymph node dissection was negative in 0 of 23 nodes. Surgical
